Clinical Trial News and Research

RSS

Autologous stem cells do not improve heart function when given three weeks after heart attack

Administering stem cells derived from patients' own bone marrow either three or seven days after a heart attack is safe but does not improve heart function six months later, according to a clinical trial supported by the National Institutes of Health (NIH).

8 Nov 2012

Carbohydrate-rich food intake may cause recurrence of colon cancer

Colon cancer survivors whose diet is heavy in complex sugars and carbohydrate-rich foods are far more likely to have a recurrence of the disease than are patients who eat a better balance of foods, a new study by Dana-Farber Cancer Institute researchers indicates.

8 Nov 2012

EpiCept, Immune Pharmaceuticals enter definitive merger agreement

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation today announced that they have entered into a definitive merger agreement. The transaction is anticipated to close during the first quarter of 2013 and is subject to satisfaction of certain customary closing conditions, including the approval of a majority of EpiCept shareholders.

8 Nov 2012

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

The US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted unanimously in support of the use of Signifor (pasireotide) for the treatment of patients with Cushing's disease who require medical therapeutic intervention.

7 Nov 2012

People more likely to take heart medicines in combo pill

People are much more likely to take heart medicines if they're combined in one pill, according to a late-breaking clinical trial presented at the American Heart Association's Scientific Sessions 2012.

7 Nov 2012

Results from liraglutide and exenatide head-to-head comparison trial on type 2 diabetes

A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded mixed results.

7 Nov 2012

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.

7 Nov 2012

Cause of heart attacks or strokes may be different in some patients treated with anti-platelet drugs

The cause of heart attacks or strokes among some patients treated with anti-platelet drugs may be different than for patients who have undergone surgical procedures to restore blood flow, according to researchers at Duke Medicine.

7 Nov 2012

Mayo Clinic and collaborators to test new ways to provide specialized TBI care

For people who are hospitalized for traumatic brain injury, recovery may involve physical and cognitive problems that linger for years. The road back to health can be even more arduous for those who live in remote rural areas and don't have access to brain rehabilitation specialists. Mayo Clinic and collaborators, have received a $2.2 million federal grant to test new ways to provide specialized TBI care, with a focus on reaching rural areas and underserved urban populations.

7 Nov 2012

$Cryopraxis/CellPraxis initiates recruitment in ReACT Phase III trial for refractory angina$

Cryopraxis/CellPraxis initiates recruitment in ReACT Phase III trial for refractory angina

Cryopraxis/CellPraxis aims to start patient recruitment for its Phase III Refractory Angina Cell Therapy Brazilian arm clinical trial by the end of 2012 or early 2013.

6 Nov 2012

Sabin initiates Part II of Na-GST-1 vaccine Phase I hookworm trial

The Sabin Vaccine Institute (Sabin) today announced the start of Part II of its Phase I clinical trial of the Na-GST-1 vaccine candidate, marking another major milestone in the progress toward developing a human hookworm vaccine.

6 Nov 2012

BioMimetic Therapeutics reports net loss of $4.6 million for third quarter 2012

BioMimetic Therapeutics, Inc. today reported its corporate highlights and financial results as of and for the three and nine months ended September 30, 2012. For the three months ended September 30, 2012, the Company reported a net loss of $4.6 million, or $0.16 per diluted share, compared to a net loss of $7.1 million, or $0.25 per diluted share, for the same period in 2011.

6 Nov 2012

Combination of mosquito nets and deltamethrin does not lead to decline in malaria

Some develop resistance. Others alter their behaviour. Mosquitoes of the genus Anopheles, the vectors of malaria, always find a way to foil human attempts to protect themselves from this disease. Researchers from the IRD and their partners have revealed their great capacity for adaptation, which weakens the strategies to combatting their presence, recommended by the WHO.

6 Nov 2012

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2012, and company highlights.

6 Nov 2012

Endo, Bioniche decide to end second Urocidin Phase III trial on non-muscle-invasive bladder cancer

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that a second Phase III clinical trial with Urocidin in non-muscle-invasive bladder cancer is being discontinued.

5 Nov 2012

PsiOxus receives UK government grant to initiate ColoAd1 Phase I/II trial for ovarian cancer

PsiOxus Therapeutics, Ltd., a development stage biotechnology company, today announced the award of a £1.7 million ($2.7 million) grant from the UK government-backed Biomedical Catalyst to initiate a Phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer.

5 Nov 2012

Study highlights potential treatment that reduces kidney growth

Autosomal-dominant polycystic kidney disease (ADPKD) is one of the most common genetic disorders, affecting one in every 1,000 people and responsible for up to ten percent of patients on dialysis worldwide. The disease is characterized by the development of cysts that lead to progressive kidney failure and necessitate dialysis or a kidney transplant in most patients aged around fifty. Moreover, the persistent cyst growth causes high blood pressure and painful complications.

5 Nov 2012

Bristol-Myers Squibb welcomes decision by NICE to recommend Yervoy for advanced melanoma

Today, Bristol-Myers Squibb is pleased to welcome the decision by The National Institute for Health and Clinical Excellence (NICE) to recommend Yervoy (ipilimumab) for the treatment of previously-treated advanced (unresectable or metastatic) melanoma within the Final Appraisal Determination (FAD).

3 Nov 2012

Pfizer, Bristol-Myers Squibb announce data from ELIQUIS clinical trial on AF

Bristol-Myers Squibb Company and Pfizer Inc. today announced that a large number of data presentations sponsored by the companies on ELIQUIS (apixaban) and the treatment of atrial fibrillation will be presented at the American Heart Association 2012 Scientific Sessions, November 3-7, 2012, in Los Angeles, California.

3 Nov 2012

Lomitapide shows promise in treating homozygous familial hypercholesterolemia

An international effort led by researchers at the Perelman School of Medicine at the University of Pennsylvania has resulted in positive phase 3 clinical trial results for a new medicine to treat patients suffering from a rare and deadly cholesterol disorder.

3 Nov 2012

Clinical Trial News and Research

Autologous stem cells do not improve heart function when given three weeks after heart attack

Carbohydrate-rich food intake may cause recurrence of colon cancer

EpiCept, Immune Pharmaceuticals enter definitive merger agreement

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

People more likely to take heart medicines in combo pill

Results from liraglutide and exenatide head-to-head comparison trial on type 2 diabetes

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Cause of heart attacks or strokes may be different in some patients treated with anti-platelet drugs

Mayo Clinic and collaborators to test new ways to provide specialized TBI care

Cryopraxis/CellPraxis initiates recruitment in ReACT Phase III trial for refractory angina

Sabin initiates Part II of Na-GST-1 vaccine Phase I hookworm trial

BioMimetic Therapeutics reports net loss of $4.6 million for third quarter 2012

Combination of mosquito nets and deltamethrin does not lead to decline in malaria

Alnylam third quarter 2012 revenues decrease to $16.8 million

Endo, Bioniche decide to end second Urocidin Phase III trial on non-muscle-invasive bladder cancer

PsiOxus receives UK government grant to initiate ColoAd1 Phase I/II trial for ovarian cancer

Study highlights potential treatment that reduces kidney growth

Bristol-Myers Squibb welcomes decision by NICE to recommend Yervoy for advanced melanoma

Pfizer, Bristol-Myers Squibb announce data from ELIQUIS clinical trial on AF

Lomitapide shows promise in treating homozygous familial hypercholesterolemia

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer